Daily News Podcast

TNF inhibitor linked to one-third drop in total mortality

Publish date: June 18, 2018

 

Receiving a TNF inhibitor for any indications cut patients’ overall mortality rate by more than one-third. Also today, HHS secretary, Alex Azar blames pharmacy benefit managers for no drop in prescription prices, a DEA ruling may have stoked illicit opioid sales, and taking a bisphosphonate holiday that lasts 2 years or longer is linked with increased risk for fracture.

Listen to the MDedge Daily News podcast for all the details on today’s top news.

Recommended Reading

Statin effect in prostate cancer may be caused by reduced inflammation
MDedge Hematology and Oncology
Smoking tied to localized prostate cancer recurrence, metastasis, death
MDedge Hematology and Oncology
Suicide rate jumps 30%
MDedge Hematology and Oncology
New cell-free DNA assays hold promise for lung cancer screening
MDedge Hematology and Oncology
Allergies linked to autism spectrum disorder in children
MDedge Hematology and Oncology
Study finds widespread use of medications with depression as side effect
MDedge Hematology and Oncology
New NIH consortium aims to coordinate pediatric research programs
MDedge Hematology and Oncology
Type 2 diabetes may promote Parkinson development
MDedge Hematology and Oncology
FDA database reveals many rheumatic and musculoskeletal adverse events on immunotherapies
MDedge Hematology and Oncology
Routine AAA screening for older men: more harm than good?
MDedge Hematology and Oncology